TerminatedNot Applicable

T Cells in Predicting Acute Graft-Versus-Host Disease in Patients Undergoing Donor Stem Cell Transplant

Stopped: Funding unavailable

United States150 participantsStarted 2006-12

Plain-language summary

RATIONALE: Studying samples of blood from patients with cancer in the laboratory may help doctors predict whether patients undergoing donor stem cell transplant will develop acute graft-versus-host disease. PURPOSE: This clinical trial is studying T cells to see how well they help in predicting acute graft-versus-host disease in patients undergoing donor stem cell transplant.

Who can participate

Age range18 Years – 120 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria: * Patients undergoing allogeneic SCT * Age \>= 18 years Exclusion criteria: * Inability to give informed consent * Patients who have not received an allogeneic SCT * Any condition which, in the opinion of the investigator, might interfere with study objective * Any reason which, in the opinion of the investigator, adds additional risk to the patient

What they're measuring

Percentage of regulatory T-lymphocytes (Tregs) at engraftment

Timeframe: day of stem cell transplant

Trial details

NCT IDNCT00651716

SponsorVanderbilt-Ingram Cancer Center

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2019-10

View on ClinicalTrials.gov More Breast Cancer trials